GLP-1受体激动剂与2型糖尿病或心血管代谢疾病患者视神经或视力威胁事件风险:随机对照试验的Meta分析
该Meta分析纳入20项随机对照试验、共83,288例2型糖尿病或心血管代谢疾病患者,平均随访2.97年。GLP-1受体激动剂使用与视神经和/或视力威胁严重不良事件复合终点风险升高无关(OR 1.20,95%CI 0.73-1.97,I2=0%),预设的缺血性视神经病变和视力丧失/障碍事件亦无显著关联。
要点
- GLP-1受体激动剂未增加视神经或视力威胁事件复合终点风险(OR 1.20,95%CI 0.73-1.97)。
- 缺血性视神经病变风险无显著升高(OR 1.50,95%CI 0.49-4.63)。
- 视力丧失/障碍事件风险无显著升高(OR 1.08,95%CI 0.60-1.94)。
核心结论
- 在2型糖尿病和心血管代谢疾病患者中,GLP-1受体激动剂与视神经/视力威胁事件风险增加无关。
研究设计与样本
- 随机对照试验的Meta分析,纳入20项已发表RCT、共83,288例2型糖尿病或心血管代谢疾病患者,遵循PRISMA进行。
- 参与者中76.4%为2型糖尿病,平均随访2.97年,估计累积暴露240,334患者年。
主要发现
- GLP-1受体激动剂与主要终点(视神经和/或视力威胁严重不良事件复合终点)风险无关(OR 1.20,95%CI 0.73-1.97,I2=0%)。
- 预设的缺血性视神经病变与GLP-1受体激动剂使用无显著关联(OR 1.50,95%CI 0.49-4.63)。
- 视力丧失/障碍事件与GLP-1受体激动剂使用无显著关联(OR 1.08,95%CI 0.60-1.94)。
关键数值与推荐
- 主要终点为视神经和/或视力威胁严重不良事件复合终点,包括缺血性视神经病变、眼缺血综合征、视乳头水肿、失明、视物模糊、视力损害和视力下降。
- 效应量为比值比(OR),主要终点OR 1.20(95%CI 0.73-1.97,I2=0%)。
临床怎么用
- 对于2型糖尿病或心血管代谢疾病患者,使用GLP-1受体激动剂时无需因视神经或视力威胁事件风险而顾虑。
- 仍需关注临床试验中以不良事件形式报告的视力相关事件。
局限性
- RCT将视力威胁事件作为不良事件报告,而非预设结局,可能影响事件识别的完整性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data concerning glucagon-like peptide 1 receptor agonists (GLP-1 RAs) on risk of ischemic optic neuropathy (ION) are conflicting. PURPOSE: We synthesize current evidence of GLP-1 RAs on risk of optic nerve or vision-threatening events from randomized controlled trials (RCTs) in patients with type 2 diabetes or cardiometabolic diseases. DATA SOURCE: A total of 83,288 participants with type 2 diabetes/cardiometabolic diseases from 20 published RCTs were analyzed following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA). STUDY SELECTION: RCTs investigating GLP-1 RAs for type 2 diabetes/cardiometabolic disease populations and reported optic nerve or vision-related adverse events were assessed. DATA EXTRACTION: Primary outcome was a composite of optic nerve and/or vision-threatening serious adverse events, including ION, ocular ischemic syndrome, papilledema, blindness, blurred vision, visual impairment, and reduced visual acuity. Odds ratios (ORs) were derived. DATA SYNTHESIS: Type 2 diabetes occurred in 76.4% of participants. Over mean follow-up duration of 2.97 years (estimated cumulative exposure of 240,334 patient-years), GLP-1 RA use was not associated with increased risk of primary end point (OR 1.20, 95% CI 0.73-1.97, I2 = 0%). Prespecified individual adverse events, including ION (OR 1.50, 95% CI 0.49-4.63), and vision loss/disturbance events (OR 1.08, 95% CI 0.60-1.94) were not significantly associated with GLP-1 RA use. LIMITATIONS: RCTs reported vision-threatening events as adverse events rather than as prespecified outcomes. CONCLUSIONS: Based on a large number of patients who contributed to a meta-analysis of RCTs involving participants with type 2 diabetes and cardiometabolic disease, GLP-1 RAs were not associated with an increased risk of optic nerve/vision-threatening events.
引用
- Li HY, Chan TK, Co Shih K, et al. GLP-1 Receptor Agonists and Risk of Optic Nerve or Vision-Threatening Events in Patients With Type 2 Diabetes or Cardiometabolic Diseases: A Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2026. PMID: 41587563. doi:10.2337/dc25-1929
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。